Patents by Inventor Samuel Herschkowitz
Samuel Herschkowitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11776675Abstract: The present disclosure relates to integrated systems, methods and apparatuses for assisting individuals in managing acute life-threatening conditions. A system in accordance with the current disclosure may comprise an electronic circuit configured to be attached to a container of a medication and one or more devices in communication with the electronic circuit in a private network. In an aspect, the one or more devices may work in concert to determine the safety level of an individual based on predetermined usage settings. In some aspects, the system may be configured to determine whether a medication would expire before its manufactured expiry date. In another aspect, the system may assist an individual in locating a medication. In a further aspect, the system may determine whether an individual is having an anaphylactic reaction. In some aspects, the system may detect a known allergen and alert the individual.Type: GrantFiled: May 21, 2020Date of Patent: October 3, 2023Assignee: Above the Fold, LLCInventors: Samuel Herschkowitz, Abby Herzig, Joshua Kornberg, Seymour Fein, Deborah Adler, Eric Freitag, Robert R. Pascazio, Matthew Chin, Gareth Brown, Stephen Kaes, Troy Yoshimoto, Ritik Dholakia, Mike Klodginski, Khoi Uong, Erin Woo, Pepin Gelardi, Theodore Ullrich
-
Publication number: 20220392601Abstract: The present disclosure relates to integrated systems, methods and apparatuses for assisting individuals in managing acute life-threatening conditions. A system in accordance with the current disclosure may comprise an electronic circuit configured to be attached to a container of a medication and one or more devices in communication with the electronic circuit in a private network. In an aspect, the one or more devices may work in concert to determine the safety level of an individual based on predetermined usage settings. In some aspects, the system may be configured to determine whether a medication would expire before its manufactured expiry date. In another aspect, the system may assist an individual in locating a medication. In a further aspect, the system may determine whether an individual is having an anaphylactic reaction. In some aspects, the system may detect a known allergen and alert the individual.Type: ApplicationFiled: May 21, 2020Publication date: December 8, 2022Applicant: Above the Fold, LLCInventors: Samuel Herschkowitz, Abby Herzig, Joshua Kornberg, Seymour Fein, Deborah Adler, Eric Freitag, Robert R. Pascazio, Matthew Chin, Gareth Brown, Stephen Kaes, Troy Yoshimoto, Ritik Dholakia, Mike Klodginski, Khoi Uong, Erin Woo, Pepin Gelardi, Theodore Ullrich
-
Patent number: 10699539Abstract: The present disclosure relates to integrated systems, methods and apparatuses for assisting individuals in managing acute life-threatening conditions. A system in accordance with the current disclosure may comprise an electronic circuit configured to be attached to a container of a medication and one or more devices in communication with the electronic circuit in a private network. In an aspect, the one or more devices may work in concert to determine the safety level of an individual based on predetermined usage settings. In some aspects, the system may be configured to determine whether a medication would expire before its manufactured expiry date. In another aspect, the system may assist an individual in locating a medication. In a further aspect, the system may determine whether an individual is having an anaphylactic reaction. In some aspects, the system may detect a known allergen and alert the individual.Type: GrantFiled: November 5, 2018Date of Patent: June 30, 2020Assignee: ABOVE THE FOLD, LLCInventors: Samuel Herschkowitz, Abby Herzig, Joshua Kornberg, Seymour Fein, Deborah Adler, Eric Freitag, Robert R. Pascazio, Matthew Chin, Gareth Brown, Stephen Kaes, Troy Yoshimoto, Ritik Dholakia, Mike Klodginski, Khoi Uong, Erin Woo, Pepin Gelardi, Theodore Ullrich
-
Patent number: 10568927Abstract: The invention provides methods and compositions for use of desmopressin in combination with a beta-3-adrenergic receptor agonist. The methods and compositions are useful in the treatment of nocturia and other urinary frequency disorders.Type: GrantFiled: November 13, 2017Date of Patent: February 25, 2020Assignee: Serenity Pharmaceuticals LLCInventors: Seymour H. Fein, Samuel Herschkowitz
-
Publication number: 20190340900Abstract: The present disclosure relates to integrated systems, methods and apparatuses for assisting individuals in managing acute life-threatening conditions. A system in accordance with the current disclosure may comprise an electronic circuit configured to be attached to a container of a medication and one or more devices in communication with the electronic circuit in a private network. In an aspect, the one or more devices may work in concert to determine the safety level of an individual based on predetermined usage settings. In some aspects, the system may be configured to determine whether a medication would expire before its manufactured expiry date. In another aspect, the system may assist an individual in locating a medication. In a further aspect, the system may determine whether an individual is having an anaphylactic reaction. In some aspects, the system may detect a known allergen and alert the individual.Type: ApplicationFiled: November 5, 2018Publication date: November 7, 2019Applicant: Above the Fold, LLCInventors: Samuel Herschkowitz, Abby Herzig, Joshua Kornberg, Seymour Fein, Deborah Adler, Eric Freitag, Robert R. Pascazio, Matthew Chin, Gareth Brown, Stephen Kaes, Troy Yoshimoto, Ritik Dholakia, Mike Klodginski, Khoi Uong, Erin Woo, Pepin Gelardi, Theodore Ullrich
-
Patent number: 10286033Abstract: The invention provides methods and compositions for use of desmopressin in combination with an alpha-adrenergic receptor antagonist. The methods and compositions are useful in the treatment of nocturia and other urinary frequency disorders.Type: GrantFiled: November 19, 2015Date of Patent: May 14, 2019Assignee: Serenity Pharmaceuticals, LLCInventors: Seymour H. Fein, Linda Cheng, Maria Cheng, Samuel Herschkowitz
-
Patent number: 10163311Abstract: The present disclosure relates to integrated systems, methods and apparatuses for assisting individuals in managing acute life-threatening conditions. A system in accordance with the current disclosure may comprise an electronic circuit configured to be attached to a container of a medication and one or more devices in communication with the electronic circuit in a private network. In an aspect, the one or more devices may work in concert to determine the safety level of an individual based on predetermined usage settings. In some aspects, the system may be configured to determine whether a medication would expire before its manufactured expiry date. In another aspect, the system may assist an individual in locating a medication. In a further aspect, the system may determine whether an individual is having an anaphylactic reaction. In some aspects, the system may detect a known allergen and alert the individual.Type: GrantFiled: February 16, 2017Date of Patent: December 25, 2018Assignee: Above the Fold, LLPInventors: Samuel Herschkowitz, Abby Herzig, Joshua Kornberg, Seymour Fein, Deborah Adler, Eric Freitag, Robert R. Pascazio, Matthew Chin, Gareth Brown, Stephen Kaes, Troy Yoshimoto, Ritik Dholakia, Mike Klodginski, Khoi Uong, Erin Woo, Pepin Gelardi, Theodore Ullrich
-
Publication number: 20180289769Abstract: The invention provides methods and compositions for use of desmopressin in combination with a beta-3-adrenergic receptor agonist. The methods and compositions are useful in the treatment of nocturia and other urinary frequency disorders.Type: ApplicationFiled: November 13, 2017Publication date: October 11, 2018Inventors: Seymour H. Fein, Samuel Herschkowitz
-
Patent number: 9925232Abstract: The invention provides methods and compositions for use of desmopressin in combination with a 5-alpha reductase inhibitor. The methods and compositions are useful in the treatment of nocturia and other urinary frequency disorders.Type: GrantFiled: July 23, 2014Date of Patent: March 27, 2018Assignee: Serenity Pharmaceuticals, LLCInventors: Seymour H. Fein, Linda Cheng, Maria Cheng, Samuel Herschkowitz
-
Patent number: 9814753Abstract: The invention provides methods and compositions for use of desmopressin in combination with a beta-3-adrenergic receptor agonist. The methods and compositions are useful in the treatment of nocturia and other urinary frequency disorders.Type: GrantFiled: July 23, 2014Date of Patent: November 14, 2017Assignee: Serenity Pharmaceuticals LLCInventors: Seymour H. Fein, Samuel Herschkowitz
-
Publication number: 20170319646Abstract: The invention provides methods and compositions for use of desmopressin in combination with an alpha-adrenergic receptor antagonist. The methods and compositions are useful in the treatment of nocturia and other urinary frequency disorders.Type: ApplicationFiled: November 19, 2015Publication date: November 9, 2017Inventors: Seymour H. Fein, Linda Cheng, Maria Cheng, Samuel Herschkowitz
-
Publication number: 20170236390Abstract: The present disclosure relates to integrated systems, methods and apparatuses for assisting individuals in managing acute life-threatening conditions. A system in accordance with the current disclosure may comprise an electronic circuit configured to be attached to a container of a medication and one or more devices in communication with the electronic circuit in a private network. In an aspect, the one or more devices may work in concert to determine the safety level of an individual based on predetermined usage settings. In some aspects, the system may be configured to determine whether a medication would expire before its manufactured expiry date. In another aspect, the system may assist an individual in locating a medication. In a further aspect, the system may determine whether an individual is having an anaphylactic reaction. In some aspects, the system may detect a known allergen and alert the individual.Type: ApplicationFiled: February 16, 2017Publication date: August 17, 2017Applicant: Above the Fold, LLCInventors: Samuel Herschkowitz, Abby Herzig, Joshua Kornberg, Seymour Fein, Deborah Adler, Eric Freitag, Robert R. Pascazio, Matthew Chin, Gareth Brown, Stephen Kaes, Troy Yoshimoto, Ritik Dholakia, Mike Klodginski, Khoi Uong, Erin Woo, Pepin Gelardi, Theodore Ullrich
-
Publication number: 20160303185Abstract: Disclosed are devices for urine voiding postponement, and methods for treating conditions such as central diabetes insipidus, enuresis, nocturia, urinary frequency or incontinence. The devices deliver a desmopressin flux through the skin of a patient in a low dose amount just necessary to achieve a desired anti-diuretic effect without undesirable side effects such as hyponatremia. The devices are designed to permit a state of normal urinary production to return quickly after the desmopressin flux is terminated.Type: ApplicationFiled: June 27, 2016Publication date: October 20, 2016Inventors: Samuel Herschkowitz, Seymour H. Fein
-
Patent number: 9375530Abstract: Disclosed are devices for urine voiding postponement, and methods for treating conditions such as central diabetes insipidus, enuresis, nocturia, urinary frequency or incontinence. The devices deliver a desmopressin flux through the skin of a patient in a low dose amount just necessary to achieve a desired anti-diuretic effect without undesirable side effects such as hyponatremia. The devices are designed to permit a state of normal urinary production to return quickly after the desmopressin flux is terminated.Type: GrantFiled: February 15, 2013Date of Patent: June 28, 2016Assignee: Allergan, Inc.Inventors: Samuel Herschkowitz, Seymour H. Fein
-
Publication number: 20150031613Abstract: The invention provides methods and compositions for use of desmopressin in combination with a beta-3-adrenergic receptor agonist. The methods and compositions are useful in the treatment of nocturia and other urinary frequency disorders.Type: ApplicationFiled: July 23, 2014Publication date: January 29, 2015Inventors: Seymour H. Fein, Samuel Herschkowitz
-
Publication number: 20150031614Abstract: The invention provides methods and compositions for use of desmopressin in combination with a 5-alpha reductase inhibitor. The methods and compositions are useful in the treatment of nocturia and other urinary frequency disorders.Type: ApplicationFiled: July 23, 2014Publication date: January 29, 2015Inventors: Seymour H. Fein, Linda Cheng, Maria Cheng, Samuel Herschkowitz
-
Patent number: 8399410Abstract: Disclosed are devices for urine voiding postponement, and methods for treating conditions such as central diabetes insipidus, enuresis, nocturia, urinary frequency or incontinence. The devices deliver a desmopressin flux through the skin of a patient in a low dose amount just necessary to achieve a desired anti-diuretic effect without undesirable side effects such as hyponatremia. The devices are designed to permit a state of normal urinary production to return quickly after the desmopressin flux is terminated.Type: GrantFiled: August 6, 2008Date of Patent: March 19, 2013Assignee: Allergan, Inc.Inventors: Samuel Herschkowitz, Seymour Fein
-
Publication number: 20100160214Abstract: Disclosed is a pharmaceutical formulation that may be used in the treatment of nocturia, primary nocturnal enuresis, incontinence, urinary frequency, diabetes insipidus, or any disease or syndrome where desmopressin therapy is useful or where safe temporary suppression of urine production may lead to beneficial health effects or increased convenience in voiding control.Type: ApplicationFiled: December 22, 2009Publication date: June 24, 2010Applicant: SERENITY PHARMACEUTICALS CORPORATIONInventors: Seymour Fein, Samuel Herschkowitz
-
Publication number: 20090042970Abstract: Disclosed are devices for urine voiding postponement, and methods for treating conditions such as central diabetes insipidus, enuresis, nocturia, urinary frequency or incontinence. The devices deliver a desmopressin flux through the skin of a patient in a low dose amount just necessary to achieve a desired anti-diuretic effect without undesirable side effects such as hyponatremia. The devices are designed to permit a state of normal urinary production to return quickly after the desmopressin flux is terminated.Type: ApplicationFiled: August 6, 2008Publication date: February 12, 2009Applicant: Serenity Pharmaceuticals CorporationInventors: Samuel Herschkowitz, Seymour Fein